Robert Nelsen was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
Name: Robert Nelsen
Organisation: Arch Venture Partners
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
LSIPR 50, Robert Nelsen, Arch Venture Partners, investment, Alnylam Pharmaceuticals, Juno Therapeutics, Vir Biotechnology, Sage Therapeutics, Illumina
